Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication
Status:
Completed
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The goal of this prospective randomized clinical trial is to compare the rate of Helicobacter
Pylori (HP) eradication after standard or dose-optimized amoxicillin quadritherapy in
patients naïve to any anti-HP treatment and with chronic HP infection documented by
histological examination. The main questions it aims to answer are:
- compare the eradication rate of H.Pylori after a standard concomitant quadritherapy with
2g of amoxicillin versus an optimized quadritherapy with 3g of amoxicillin, in Tunisian
population
- Identify different factors associated with poor therapeutic response Patients were
randomly assigned to either standard quadruple therapy (Qs-14: amoxicillin 1g twice
daily, clarithromycin 500mg twice daily, metronidazole 500mg twice daily and
esomeprazole 40mg twice daily for 14 days), or optimized quadruple therapy (Qo-14:
amoxicillin 1g three times a day, clarithromycin 500mg twice daily, metronidazole 500mg
twice daily and esomeprazole 40mg twice daily for 14 days). Eradication control was
performed by urea breath test.